NCT06698003View on ClinicalTrials.gov

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

PHASE2RecruitingINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

November 15, 2029

Study Completion Date

November 15, 2029

Conditions
T-Cell Leukemia/Lymphoma, AdultT-cell Leukemia/LymphomaT-cell LeukemiaLymphoma
Interventions
DRUG

Mogamulizumab

Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (All protocol activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (All protocol activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities), Commack

07920

RECRUITING

Memorial Sloan Kettering at Basking Ridge (All protocol activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (All protocol activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER